Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder

American Journal of Psychiatry

Volumn 169, Issue 8, 2012, Pages 851-859

  Saricicek, Aybala ^a,b,c,d   Esterlis, Irina ^a,b,c,d   Maloney, Kathleen H ^a,b,c,d   Mineur, Yann S ^a,b,c,d   Ruf, Barbara M ^a,b,c,d   Muralidharan, Anjana ^a,b,c,d   Chen, Jason I ^a,b,c,d   Cosgrove, Kelly P ^a,b,c,d   Kerestes, Rebecca ^a,b,c,d   Ghose, Subroto ^a,b,c,d   Tamminga, Carol A ^a,b,c,d   Pittman, Brian ^a,b,c,d   Bois, Frederic ^a,b,c,d   Tamagnan, Gilles ^a,b,c,d   Seibyl, John ^a,b,c,d   Picciotto, Marina R ^a,b,c,d   Staley, Julie K ^a,b,c,d   Bhagwagar, Zubin ^a,b,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 I A 85380 I 123; NICOTINIC RECEPTOR BETA2; RADIOLIGAND; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ANXIETY; ARTICLE; AUTOPSY; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOTRAUMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84864827320     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.11101546     Document Type: Article

References (52)

1. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR: Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 7:525-535
2. Owens MJ, Overstreet DH, Knight DL, Rezvani AH, Ritchie JC, Bissette G, Janowsky DS, Nemeroff CB: Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. Neuropsychopharmacology 1991; 4:87-93
3. Dilsaver SC: Pathophysiology of "cholinoceptor supersensitivity" in affective disorders. Biol Psychiatry 1986; 21:813-829
4. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ: A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2:632-635
5. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL: Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol. Science 1980; 209:1545-1546 (Pubitemid 11235154)
6. Janowsky DS, Overstreet DH: Cholinergic dysfunction in depression. Pharmacol Toxicol 1990; 66(suppl 3):100-111 (Pubitemid 20110989)
7. Zimmerman M, Chelminski I, McDermut W: Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry 2002; 63:187-193 (Pubitemid 34407076)
8. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-997 (Pubitemid 16073948)
9. Poirier MF, Canceil O, Bayle F, Millet B, Bourdel MC, Moatti C, Olie JP, Attar-Levy D: Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:529-537 (Pubitemid 34252947)
10. Glassman AH: Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993; 150:546-553
11. Breslau N, Kilbey MM, Andreski P: Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry 1993; 50:31-35 (Pubitemid 23026986)
12. Quattrocki E, Baird A, Yurgelun-Todd D: Biological aspects of the link between smoking and depression. Harv Rev Psychiatry 2000; 8:99-110 (Pubitemid 30659210)
13. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA: Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61:1107-1115 (Pubitemid 39463411)
14. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS, Kling MA: Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) 1999; 142:193-199 (Pubitemid 29190855)
15. Rabenstein RL, Caldarone BJ, Picciotto MR: The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) 2006; 189:395-401 (Pubitemid 44772820)
16. Mineur YS, Somenzi O, Picciotto MR: Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidechiatric pressant-like properties in male C57BL/6J mice. Neuropharmacology 2007; 52:1256-1262 (Pubitemid 46527701)
17. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, Picciotto MR: Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol 2009; 605:114-116
18. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR: High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 2004; 56:657-664 (Pubitemid 39446847)
19. Salin-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colin R: Effects of transdermal nicotine on mood and sleep in non-smoking major depressed patients. Psychopharmacology (Berl) 1995; 121:476-479
20. McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED: Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2006; 189:125-133 (Pubitemid 44607266)
21. George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD: Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol 2008; 28:340-344
22. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C: Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009; 65:144-149
23. Musachio JL, Villemagne VL, Scheffel UA, Dannals RF, Dogan AS, Yokoi F, Wong DF: Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. Nucl Med Biol 1999; 26:201-207 (Pubitemid 29125338)
24. Fujita M, Tamagnan G, Zoghbi SS, Al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB: Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. J Nucl Med 2000; 41:1552-1560
25. Staley JK, van Dyck CH, Weinzimmer D, Brenner E, Baldwin RM, Tamagnan GD, Riccardi P, Mitsis E, Seibyl JP: 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med 2005; 46:1466-1472 (Pubitemid 46173258)
26. Bhagwagar Z, Cowen PJ: 'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol Med 2008; 38:307-313 (Pubitemid 351311671)
27. Fujita M, Al-Tikriti MS, Tamagnan G, Zoghbi SS, Bozkurt A, Baldwin RM, Innis RB: Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse 2003; 48:116-122 (Pubitemid 36444336)
28. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders - Clinician Version (SCID-CV). Washington, DC, American Psychiatric Press, 1997
29. Beck AT, Steer RA, Brown GK: Beck Depression Inventory, 2nd ed, Manual. San Antonio, Tex, Psychological Corp, 1996
30. Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. J Applied Psychol Measurement 1977; 1:385-401
31. Spielberger CD: State-Trait Anxiety Inventory. Palo Alto, Calif, Consulting Psychologists Press, 1985
32. Costa PT Jr, McCrae RR: NEO PI-R Professional Manual. Odessa, Fla, Psychological Assessment Resources, 1992
33. Bernstein DP, Fink L: Childhood Trauma Questionnaire: A Retrospective Self-Report (CTQ). San Antonio, Tex, Harcourt Assessment, 1997
34. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
35. Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ: Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 2004; 161:368-370 (Pubitemid 38419291)
36. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ: Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 2004; 9:386-392 (Pubitemid 38534699)
37. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P: Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907. Am J Psychiatry 2006; 163:1580-1587 (Pubitemid 44465759)
38. Esterlis I, Cosgrove KP, Batis JC, Bois F, Stiklus SM, Perkins E, Seibyl JP, Carson RE, Staley JK: Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med 2010; 51:1226-1233
39. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O'Malley S, van Dyck CH: Human tobacco smokers in early abstinence have higher levels of beta2&z.ast; nicotinic acetylcholine receptors than nonsmokers. J Neurosci 2006; 26:8707-8714 (Pubitemid 44319406)
40. Zoghbi SS, Tamagnan G, Baldwin MF, Al-Tikriti MS, Amici L, Seibyl JP, Innis RB: Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2- azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol 2001; 28:91-96 (Pubitemid 32155969)
41. Cosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, Perry E, Maciejewski PK, Epperson CN, Allen S, O'Malley S, Mazure CM, Seibyl JP, van Dyck CH, Staley JK: 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med 2007; 48:1633-1640 (Pubitemid 47572711)
42. Bora E, Fornito A, Pantelis C, Yücel M: Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord 2012; 138:9-18 43.
43. van Tol MJ, van der Wee NJ, van den Heuvel OA, Nielen MM, Demenescu LR, Aleman A, Renken R, van Buchem MA, Zitman FG, Veltman DJ: Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry 2010; 67:1002-1011
44. Ashburner J, Friston KJ: Unified segmentation. Neuroimage 2005; 26:839-851 (Pubitemid 40825026)
45. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, Tamminga CA: Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123:1-11
46. Bhagwagar Z, Murthy N, Selvaraj S, Hinz R, Taylor M, Fancy S, Grasby P, Cowen P: 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry 2007; 164:1858-1865 (Pubitemid 351739239)
47. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman E, Matthews PM, Cowen PJ: Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008; 11:255-260 (Pubitemid 351231824)
48. Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, Riganti L, Gaimarri A, McKeith IG, Perry RH, Aarsland D, Larsen JP, Sher E, Beattie R, Clementi F, Court JA: Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 2006; 23:481-489 (Pubitemid 44097037)
49. Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T, Stiklus S, Krishnan-Sarin S, O'Malley S, Perry E, Tamagnan G, Seibyl JP, Staley JK: Beta2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 2009; 66:666-676
50. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB: The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008; 33:693-710
51. Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA: Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med 2008; 49:1628-1635
52. Shytle R, Sheehan D, Sanberg P, Arias H: Neuronal nicotinic receptors as therapeutic targets for mood disorders, in Pharmacology of Nicotinic Acetylcholine Receptors From the Basic and Therapeutic Perspectives. Edited by Arias H. Trivandrum, Kerala, India, Research Signpost, 2011, pp 187-198